Stock information

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet consectetur. Integer eget magna mollis eleifend. Ullamcorper eu mauris luctus amet nullam.

  • Lorem ipsum dolor sit amet consectetur.
  • Integer eget magna mollis eleifend.
  • Ullamcorper eu mauris luctus amet nullam.
Lorem ipsum dolor

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet consectetur. Integer eget magna mollis eleifend. Ullamcorper eu mauris luctus amet nullam.

  • Lorem ipsum dolor sit amet consectetur.
  • Integer eget magna mollis eleifend.
  • Ullamcorper eu mauris luctus amet nullam.
Lorem ipsum dolor

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet consectetur. Integer eget magna mollis eleifend. Ullamcorper eu mauris luctus amet nullam.

  • Lorem ipsum dolor sit amet consectetur.
  • Integer eget magna mollis eleifend.
  • Ullamcorper eu mauris luctus amet nullam.
Lorem ipsum dolor

Lorem ipsum dolor
sit amet consectetur

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet consectetur. Integer eget magna mollis eleifend. Ullamcorper eu mauris luctus amet nullam. Feugiat mi libero lacus in ac magna turpis viverra. Sagittis odio nulla et cras quis orci. Turpis ultricies non mauris nulla et.
Lorem ipsum dolor

Lorem ipsum dolor sit amet

Lorem ipsum dolor sit amet consectetur. Integer eget magna mollis eleifend. Ullamcorper eu mauris luctus amet nullam. Feugiat mi libero lacus in ac magna turpis viverra. Sagittis odio nulla et cras quis orci. Turpis ultricies non mauris nulla et.
Lorem ipsum dolor

Latest news

press release investor

eXoZymes to host second quarter 2025 update on Tuesday August 12, 2025, at 5PM EST

Los Angeles, CA -- August 7, 2025 -- Today, eXoZymes Inc. (NASDAQ: EXOZ) (“eXoZymes”) - a pioneer of AI-engineered enzymes that can transform sustainable feedstock into nutraceuticals, medicines, and other essential chemicals - plans to host a webinar on Tuesday, August 12, 2025 at 5:00 PM Eastern Time to discuss its results for the second quarter of 2025.

Read more